MeSH term
Frequency | Condition_Probility | Adult | 252 | 0.0 |
Antihypertensive Agents/therapeutic use | 2 | 2.0 |
Blood Glucose/metabolism | 4 | 0.0 |
Diabetes Mellitus, Type 2/*epidemiology/prevention & control | 2 | 7.0 |
*Diet, Reducing | 2 | 2.0 |
*Exercise | 4 | 2.0 |
Humans | 704 | 0.0 |
Incidence | 5 | 0.0 |
Male | 359 | 0.0 |
Middle Aged | 163 | 0.0 |
Reference Values | 25 | 0.0 |
Risk Factors | 21 | 0.0 |
Smoking/adverse effects | 4 | 1.0 |
*Smoking Cessation | 2 | 5.0 |
United States/epidemiology | 3 | 0.0 |
Weight Loss | 2 | 1.0 |
Aged | 100 | 0.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Comparative Study | 127 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Female | 327 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
Prognosis | 11 | 0.0 |
African Americans | 2 | 1.0 |
Cohort Studies | 13 | 0.0 |
European Continental Ancestry Group | 10 | 1.0 |
Infant, Newborn | 29 | 0.0 |
Pregnancy | 23 | 0.0 |
Research Support, Non-U.S. Gov't | 332 | 0.0 |
Urban Population | 3 | 2.0 |
Animals | 91 | 0.0 |
Cells, Cultured | 14 | 0.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
Rats | 17 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Species Specificity | 5 | 0.0 |
Adolescent | 86 | 0.0 |
*Body Composition | 33 | 29.0 |
*Body Constitution | 2 | 7.0 |
Child | 64 | 0.0 |
*Sex Characteristics | 3 | 2.0 |
Aged, 80 and over | 27 | 0.0 |
Predictive Value of Tests | 9 | 0.0 |
Radiotherapy Dosage | 3 | 2.0 |
Regression Analysis | 26 | 1.0 |
Retrospective Studies | 8 | 0.0 |
Sensitivity and Specificity | 11 | 0.0 |
Survival Analysis | 4 | 0.0 |
Time Factors | 45 | 0.0 |
Treatment Failure | 8 | 2.0 |
Argentina/epidemiology | 2 | 13.0 |
Child, Preschool | 31 | 0.0 |
HIV Protease/genetics | 3 | 12.0 |
HIV-1/classification/*genetics | 2 | 9.0 |
HIV-1 Reverse Transcriptase/genetics | 3 | 8.0 |
Infant | 38 | 0.0 |
Phylogeny | 7 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 29 | 0.0 |
Cattle | 5 | 0.0 |
Chronic Disease | 5 | 0.0 |
Double-Blind Method | 12 | 0.0 |
Follow-Up Studies | 14 | 0.0 |
Statistics | 5 | 1.0 |
Transplantation, Heterologous | 3 | 0.0 |
Treatment Outcome | 15 | 0.0 |
*Breast Feeding | 18 | 27.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 109 | 0.0 |
Algorithms | 3 | 0.0 |
Multivariate Analysis | 5 | 0.0 |
Prostate-Specific Antigen/*blood | 9 | 10.0 |
Anthropometry | 15 | 6.0 |
Body Composition/physiology | 6 | 10.0 |
Body Height/physiology | 2 | 12.0 |
Body Mass Index | 22 | 2.0 |
Body Weight/physiology | 4 | 5.0 |
Cross-Sectional Studies | 6 | 0.0 |
Skinfold Thickness | 19 | 26.0 |
Electroconvulsive Therapy/*methods | 2 | 66.0 |
Laterality | 2 | 3.0 |
Age Factors | 16 | 0.0 |
Analysis of Variance | 14 | 0.0 |
*Electric Impedance | 3 | 37.0 |
Probability | 4 | 0.0 |
Sex Factors | 9 | 0.0 |
*Skinfold Thickness | 4 | 66.0 |
Blood Flow Velocity | 7 | 7.0 |
Cerebrovascular Circulation | 2 | 3.0 |
*Hemorheology | 2 | 7.0 |
Linear Models | 7 | 1.0 |
Temperature | 3 | 0.0 |
Blood Glucose/*metabolism | 3 | 1.0 |
Infant Food | 6 | 26.0 |
Prospective Studies | 18 | 0.0 |
Androgen Antagonists/therapeutic use | 2 | 9.0 |
Survival Rate | 3 | 0.0 |
English Abstract | 42 | 0.0 |
Oxygen/blood | 4 | 3.0 |
Mutagenicity Tests | 4 | 2.0 |
Cookery | 2 | 3.0 |
Genotype | 30 | 0.0 |
Muscle, Skeletal/physiology | 4 | 10.0 |
Quality Control | 2 | 1.0 |
Taste | 3 | 25.0 |
Age of Onset | 4 | 0.0 |
Alleles | 96 | 1.0 |
Complement 3/*genetics | 14 | 23.0 |
Complement 4a/*genetics | 6 | 17.0 |
Complement 4b/*genetics | 6 | 17.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
HLA-B Antigens/*genetics | 6 | 2.0 |
Phenotype | 101 | 1.0 |
Body Water/metabolism | 3 | 9.0 |
Breast Feeding | 10 | 16.0 |
Cross-Over Studies | 2 | 0.0 |
Milk | 2 | 10.0 |
Osmolar Concentration | 3 | 0.0 |
Adipose Tissue/*anatomy & histology | 16 | 28.0 |
Body Composition/*physiology | 9 | 25.0 |
Body Constitution | 3 | 2.0 |
Electric Impedance | 8 | 14.0 |
Longitudinal Studies | 7 | 0.0 |
*Respiration | 4 | 10.0 |
Hydrolysis | 3 | 0.0 |
Immunoglobulin G/blood | 2 | 0.0 |
Leukocytes, Mononuclear/immunology | 2 | 0.0 |
Arm/physiology | 2 | 25.0 |
Body Weight | 27 | 4.0 |
Leg/physiology | 4 | 22.0 |
Muscle, Skeletal/*physiology | 12 | 14.0 |
Physical Fitness/*physiology | 4 | 11.0 |
Seasons | 3 | 2.0 |
Cloning, Molecular | 10 | 0.0 |
HIV Infections/*epidemiology/virology | 2 | 50.0 |
HIV-1/*classification/*genetics | 2 | 33.0 |
Heteroduplex Analysis | 2 | 2.0 |
Molecular Sequence Data | 24 | 0.0 |
*Recombination, Genetic | 4 | 1.0 |
Sequence Analysis, DNA | 7 | 0.0 |
South America/epidemiology | 2 | 50.0 |
Prevalence | 4 | 0.0 |
Models, Neurological | 2 | 1.0 |
Aerospace Medicine | 2 | 8.0 |
Blood Flow Velocity/*physiology | 2 | 33.0 |
Blood Pressure/physiology | 4 | 2.0 |
Heart Rate/physiology | 7 | 7.0 |
Leg/*blood supply | 3 | 9.0 |
Regional Blood Flow | 15 | 12.0 |
Densitometry, X-Ray | 14 | 9.0 |
Complement 2/genetics | 21 | 42.0 |
Complement 4/genetics | 20 | 32.0 |
*Major Histocompatibility Complex | 26 | 8.0 |
Polymorphism, Genetic | 54 | 1.0 |
Tumor Necrosis Factor-alpha/genetics | 4 | 1.0 |
Blood Physiology | 2 | 2.0 |
Culture Media/pharmacology | 2 | 2.0 |
Mice | 22 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Transfection | 4 | 0.0 |
*Circadian Rhythm | 2 | 0.0 |
Immunoblotting | 10 | 0.0 |
Swimming/*physiology | 2 | 13.0 |
Amino Acid Sequence | 14 | 0.0 |
Cell Line | 10 | 0.0 |
In Vitro | 13 | 0.0 |
Rabbits | 8 | 0.0 |
Blood Glucose/analysis | 6 | 0.0 |
Blood Pressure | 7 | 1.0 |
Body Height | 15 | 9.0 |
Insulin Resistance/*physiology | 2 | 2.0 |
Leptin/*blood | 5 | 6.0 |
*Asian Continental Ancestry Group | 2 | 3.0 |
Body Composition | 12 | 5.0 |
*Body Mass Index | 9 | 10.0 |
India | 5 | 1.0 |
Obesity/*diagnosis | 2 | 50.0 |
ROC Curve | 2 | 1.0 |
Cholesterol/blood | 5 | 0.0 |
Insulin/blood | 6 | 0.0 |
Insulin Resistance | 4 | 2.0 |
*Lactation | 2 | 6.0 |
Triglycerides/blood | 9 | 0.0 |
Adipose Tissue/pathology | 4 | 13.0 |
Anthropometry/methods | 2 | 33.0 |
Sex Characteristics | 7 | 1.0 |
Spain | 5 | 1.0 |
*Adipose Tissue | 4 | 11.0 |
Reproducibility of Results | 11 | 0.0 |
Heart Rate | 11 | 4.0 |
Laser-Doppler Flowmetry | 3 | 7.0 |
Electromyography | 20 | 10.0 |
Movement | 2 | 3.0 |
Nociceptors/*physiology | 2 | 15.0 |
Reflex/*physiology | 6 | 26.0 |
Italy | 13 | 2.0 |
Rickettsia conorii/*immunology | 2 | 100.0 |
Adipose Tissue/physiology | 2 | 9.0 |
Chi-Square Distribution | 4 | 0.0 |
*Alleles | 21 | 1.0 |
Base Sequence | 17 | 0.0 |
Acoustic Stimulation | 3 | 3.0 |
Auditory Cortex/*physiology | 3 | 42.0 |
Auditory Perception/*physiology | 2 | 7.0 |
Macaca fascicularis | 2 | 0.0 |
Psychoacoustics | 3 | 20.0 |
Bicarbonates/blood | 3 | 25.0 |
Hydrogen-Ion Concentration | 7 | 0.0 |
Renal Dialysis | 3 | 0.0 |
Arousal/*physiology | 2 | 6.0 |
Mice, Nude | 2 | 0.0 |
Tumor Cells, Cultured | 7 | 0.0 |
*Electromyography | 3 | 25.0 |
Exercise Test | 8 | 3.0 |
Knee/*physiology | 3 | 75.0 |
Muscle Fatigue/physiology | 2 | 28.0 |
Biological Markers/blood | 2 | 0.0 |
Hemoglobins/metabolism | 2 | 1.0 |
Leg/blood supply | 3 | 9.0 |
Oxygen Consumption/*physiology | 2 | 6.0 |
Regional Blood Flow/physiology | 6 | 12.0 |
Heart Ventricles/physiopathology | 3 | 7.0 |
Disease Progression | 4 | 0.0 |
Disease-Free Survival | 4 | 0.0 |
*Polymorphism, Genetic | 54 | 1.0 |
*Prostatectomy | 4 | 14.0 |
Biofeedback (Psychology) | 2 | 40.0 |
Hypoglycemic Agents/*therapeutic use | 2 | 3.0 |
Lipids/*metabolism | 2 | 0.0 |
Wakefulness/*physiology | 2 | 12.0 |
Aerosols | 2 | 2.0 |
Smoking | 3 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Length of Stay | 2 | 2.0 |
Electric Stimulation | 6 | 2.0 |
Nerve Fibers, Myelinated/*physiology | 2 | 33.0 |
Neurons, Afferent/physiology | 3 | 10.0 |
Reaction Time/physiology | 3 | 3.0 |
Skin/*innervation | 3 | 14.0 |
Sural Nerve/physiology | 2 | 40.0 |
Walking/*physiology | 3 | 37.0 |
Exercise/*physiology | 6 | 1.0 |
*Leg | 2 | 20.0 |
Muscle Fatigue/*physiology | 4 | 30.0 |
Gait/*physiology | 4 | 33.0 |
Chromosome Mapping | 25 | 0.0 |
France | 5 | 1.0 |
HLA Antigens/*genetics | 58 | 6.0 |
Haplotypes | 25 | 1.0 |
*Linkage Disequilibrium | 2 | 1.0 |
Major Histocompatibility Complex/*genetics | 11 | 7.0 |
Biomechanics | 5 | 4.0 |
Knee Joint/*physiology | 3 | 75.0 |
Weight Lifting/*physiology | 4 | 25.0 |
*Infant Nutrition | 5 | 41.0 |
Milk, Human/*chemistry | 2 | 4.0 |
Aging/*physiology | 4 | 1.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Cytokines/*blood | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 9 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Interferon Type II/blood | 2 | 1.0 |
Interleukin-4/blood | 2 | 4.0 |
Statistics, Nonparametric | 2 | 0.0 |
Adipose Tissue/metabolism | 5 | 4.0 |
Electric Conductivity | 2 | 1.0 |
Energy Metabolism | 3 | 1.0 |
*Growth | 6 | 20.0 |
*Infant Food | 13 | 36.0 |
Physical Endurance/*physiology | 2 | 4.0 |
Physical Fitness | 5 | 20.0 |
Running/*physiology | 3 | 7.0 |
Alphavirus Infections/*epidemiology | 2 | 100.0 |
Schizophrenia/*genetics | 3 | 1.0 |
Syndrome | 3 | 0.0 |
Lymphocytes/*immunology | 3 | 0.0 |
Turkey | 3 | 2.0 |
Trihalomethanes | 2 | 100.0 |
Random Allocation | 4 | 0.0 |
*Life Style | 3 | 5.0 |
*DNA Damage | 2 | 0.0 |
Mutation | 4 | 0.0 |
Australia | 3 | 1.0 |
Leukocyte Count | 2 | 0.0 |
Solubility | 4 | 0.0 |
Complement 3/*immunology | 2 | 3.0 |
Complement 4/*immunology | 3 | 15.0 |
Complement Factor B/*immunology | 4 | 66.0 |
Hemolysis | 7 | 2.0 |
Morbidity | 2 | 3.0 |
Korea | 5 | 2.0 |
Case-Control Studies | 4 | 0.0 |
Food Handling | 2 | 15.0 |
Lymphocyte Activation | 7 | 0.0 |
Indicator Dilution Techniques | 4 | 21.0 |
*Kidney Transplantation | 3 | 0.0 |
Postoperative Period | 2 | 0.0 |
Biological Markers | 4 | 0.0 |
Bone Density | 5 | 3.0 |
Insulin/metabolism | 2 | 1.0 |
Insulin-Like Growth Factor I/metabolism | 5 | 2.0 |
Postmenopause | 2 | 1.0 |
Complement Factor B/analysis/*genetics | 5 | 83.0 |
DNA/genetics | 5 | 0.0 |
HLA Antigens/genetics | 23 | 7.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Hydroxylation | 3 | 0.0 |
Liver/enzymology | 2 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
*Nutritional Status | 6 | 7.0 |
Atrophy | 2 | 1.0 |
Blood Volume | 4 | 8.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Electrophoresis, Agar Gel | 14 | 2.0 |
Isoelectric Focusing | 21 | 3.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Polymorphism, Restriction Fragment Length | 16 | 0.0 |
Variation (Genetics) | 15 | 0.0 |
Evolution | 2 | 0.0 |
Genes, Structural | 5 | 0.0 |
Guinea Pigs | 3 | 0.0 |
United States | 3 | 0.0 |
Oxygen Consumption/physiology | 5 | 7.0 |
Greece | 2 | 2.0 |
Japan | 19 | 1.0 |
Muscle Contraction/*physiology | 2 | 4.0 |
*Biofeedback (Psychology) | 4 | 66.0 |
Complement Factor B/*genetics | 93 | 72.0 |
Combined Modality Therapy | 3 | 0.0 |
Indonesia | 2 | 8.0 |
Cell Separation | 2 | 0.0 |
Tidal Volume | 2 | 28.0 |
*Energy Intake | 6 | 16.0 |
Energy Metabolism/*physiology | 3 | 3.0 |
Leptin | 3 | 2.0 |
Macaca | 2 | 2.0 |
Body Composition/*drug effects | 2 | 15.0 |
*African Continental Ancestry Group | 4 | 3.0 |
Forecasting | 6 | 1.0 |
Complement 2/*deficiency | 2 | 3.0 |
European Continental Ancestry Group/*genetics | 3 | 0.0 |
Genetic Screening | 3 | 0.0 |
Haplotypes/*genetics | 4 | 2.0 |
Histocompatibility Antigens Class I/genetics | 3 | 3.0 |
Histocompatibility Antigens Class II/genetics | 17 | 14.0 |
Linkage (Genetics) | 43 | 1.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Interleukin-10/blood | 2 | 2.0 |
Diet | 4 | 1.0 |
Fluorescent Antibody Technique | 8 | 0.0 |
Lipids/blood | 2 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 2 | 0.0 |
*Milk, Human | 5 | 38.0 |
Muscle, Skeletal/innervation/*physiology | 2 | 28.0 |
Skin/innervation | 2 | 11.0 |
Blister/*immunology | 2 | 66.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Blood Flow Velocity/physiology | 2 | 8.0 |
Hemodynamic Processes/*physiology | 3 | 9.0 |
Cause of Death | 2 | 1.0 |
Cerebral Cortex/*physiology | 2 | 4.0 |
Muscle, Skeletal/*innervation | 2 | 28.0 |
Reaction Time/*physiology | 2 | 11.0 |
*Tomography, X-Ray Computed | 2 | 2.0 |
Abdomen | 2 | 2.0 |
Adipose Tissue/anatomy & histology | 4 | 14.0 |
Plethysmography/*methods | 2 | 40.0 |
Insulin Resistance/physiology | 2 | 4.0 |
Energy Intake | 6 | 3.0 |
Fasting | 3 | 0.0 |
Insulin-Like Growth Factor I/analysis | 2 | 1.0 |
Triiodothyronine/blood | 2 | 0.0 |
Albumins/metabolism | 2 | 1.0 |
Creatinine/blood | 4 | 1.0 |
Histocytochemistry | 3 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Chromatography, Gel | 4 | 0.0 |
Iodide Peroxidase/immunology | 2 | 3.0 |
Radioimmunoassay | 3 | 0.0 |
Thyroglobulin/immunology | 3 | 5.0 |
Evaluation Studies | 8 | 1.0 |
Complement/*analysis | 3 | 1.0 |
Skin Diseases, Vesiculobullous/*immunology | 2 | 9.0 |
Exertion/*physiology | 2 | 3.0 |
Autonomic Nervous System/*physiopathology | 2 | 10.0 |
Dogs | 4 | 0.0 |
*Insulin Resistance | 3 | 1.0 |
Norepinephrine/blood | 2 | 1.0 |
Cercopithecus aethiops | 2 | 0.0 |
Interferon Type I, Recombinant/*pharmacology | 2 | 4.0 |
Mice, Inbred BALB C | 2 | 0.0 |
*Variation (Genetics) | 10 | 0.0 |
Vero Cells | 2 | 0.0 |
Virus Replication | 2 | 0.0 |
B-Lymphocytes/immunology | 4 | 0.0 |
Blotting, Southern | 5 | 0.0 |
Histocompatibility Testing | 15 | 1.0 |
Lymphocyte Culture Test, Mixed | 11 | 1.0 |
Major Histocompatibility Complex | 10 | 4.0 |
Swine | 5 | 0.0 |
Brazil | 6 | 2.0 |
Complement/*genetics | 18 | 31.0 |
Complement Factor B/genetics | 32 | 45.0 |
*Gene Frequency | 12 | 2.0 |
Indians, South American/*genetics | 3 | 4.0 |
*Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Steroid 21-Hydroxylase/genetics | 5 | 11.0 |
Body Temperature | 6 | 6.0 |
Leg | 2 | 4.0 |
Oxygen Consumption | 9 | 3.0 |
Adipose Tissue | 4 | 7.0 |
*Anthropometry | 4 | 12.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Australia/epidemiology | 3 | 4.0 |
*Epidemiology, Molecular | 2 | 11.0 |
Sequence Alignment | 3 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 12 | 0.0 |
Questionnaires | 3 | 0.0 |
*Milk | 2 | 28.0 |
*Aging | 2 | 1.0 |
Behavior, Animal | 2 | 2.0 |
Binding Sites | 5 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Cardiovascular System/*physiopathology | 2 | 18.0 |
*Cold | 2 | 3.0 |
Skin/blood supply | 3 | 4.0 |
Skin Temperature | 5 | 14.0 |
Vasoconstriction | 3 | 17.0 |
*Ethnic Groups | 3 | 2.0 |
*Genetics, Population | 7 | 1.0 |
India/epidemiology | 2 | 2.0 |
*Bottle Feeding | 2 | 66.0 |
*Military Personnel | 2 | 6.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Immunoglobulin G/*metabolism | 2 | 3.0 |
Thyrotropin/metabolism | 2 | 3.0 |
Densitometry | 6 | 4.0 |
Injections, Intramuscular | 2 | 1.0 |
Blood Urea Nitrogen | 4 | 6.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Blood Proteins/*genetics | 13 | 8.0 |
Models, Genetic | 3 | 0.0 |
Ethnic Groups/*genetics | 6 | 3.0 |
Complement 2/*genetics | 12 | 26.0 |
Complement 4/*genetics | 33 | 23.0 |
England | 5 | 4.0 |
Gene Frequency | 97 | 2.0 |
Cell Line, Tumor | 2 | 0.0 |
ABO Blood-Group System/genetics | 3 | 7.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Complement Factor B/analysis | 4 | 9.0 |
HLA-DR Antigens/analysis | 4 | 0.0 |
Wales | 2 | 11.0 |
Body Water | 2 | 25.0 |
Glucose/metabolism | 2 | 0.0 |
Lipids/*blood | 3 | 0.0 |
Haplotypes/*immunology | 2 | 8.0 |
Molar | 2 | 10.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Complement/genetics | 7 | 25.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Swine/*genetics | 2 | 1.0 |
ATP-Binding Cassette Transporters/*genetics | 2 | 0.0 |
HLA-D Antigens/genetics | 4 | 10.0 |
HLA-DR Antigens/genetics | 10 | 2.0 |
Blotting, Northern | 2 | 0.0 |
*Linkage (Genetics) | 17 | 1.0 |
Chromosomes, Human, Pair 6 | 4 | 2.0 |
South Africa | 3 | 2.0 |
Vitamin D-Binding Protein/*genetics | 2 | 3.0 |
Pressure | 3 | 2.0 |
*Body Temperature | 4 | 15.0 |
Heart Rate/*physiology | 2 | 6.0 |
Respiration/*physiology | 2 | 25.0 |
HLA-C Antigens/genetics | 3 | 3.0 |
Histocompatibility Antigens Class II/*genetics | 5 | 2.0 |
Blood Proteins/genetics | 2 | 3.0 |
Erythrocytes/enzymology | 2 | 0.0 |
Europe | 3 | 1.0 |
Motor Neurons/physiology | 2 | 4.0 |
Movement/*physiology | 2 | 5.0 |
Nitrogen/urine | 2 | 22.0 |
Nutrition | 2 | 5.0 |
Erythrocytes/*enzymology | 4 | 0.0 |
Genetic Markers/genetics | 4 | 0.0 |
Genetics, Population | 3 | 0.0 |
Complement 4a/genetics | 6 | 31.0 |
Complement 4b/genetics | 7 | 33.0 |
Body Surface Area | 2 | 10.0 |
Polymorphism, Genetic/*genetics | 9 | 0.0 |
Genetic Markers | 23 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
HLA Antigens/*immunology | 3 | 1.0 |
Immunoglobulin Allotypes | 2 | 25.0 |
Epithelial Cells | 2 | 0.0 |
Regional Blood Flow/drug effects | 2 | 1.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Hemodynamic Processes | 4 | 2.0 |
Blood Proteins/*analysis | 2 | 1.0 |
Islam | 2 | 18.0 |
Jordan | 3 | 21.0 |
HLA Antigens/*analysis/immunology | 2 | 11.0 |
Bladder/*physiopathology | 2 | 66.0 |
Cardiac Output | 3 | 6.0 |
Immunogenetics | 4 | 8.0 |
Terminology | 3 | 2.0 |
European Continental Ancestry Group/genetics | 6 | 0.0 |
*Phenotype | 5 | 1.0 |
*Muscle Contraction | 3 | 9.0 |
Body Weight/drug effects | 2 | 1.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Postpartum Period | 3 | 3.0 |
Multigene Family | 3 | 0.0 |
Restriction Mapping | 2 | 0.0 |
*Haplotypes | 9 | 3.0 |
Pedigree | 50 | 0.0 |
DNA Probes | 2 | 0.0 |
Gene Frequency/genetics | 7 | 1.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Blood Pressure/*physiology | 2 | 2.0 |
Complement Factor B/*analysis/genetics | 2 | 50.0 |
HLA Antigens/*analysis/genetics | 4 | 4.0 |
Immunophenotyping | 2 | 0.0 |
Isoantigens/analysis | 2 | 12.0 |
Bottle Feeding | 2 | 18.0 |
Dietary Proteins/*administration & dosage/metabolism | 2 | 40.0 |
Weight Gain | 2 | 3.0 |
Blood Group Antigens/*genetics | 7 | 6.0 |
Lod Score | 5 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Electrophoresis, Cellulose Acetate | 2 | 5.0 |
Forearm/*blood supply | 2 | 9.0 |
Immersion | 2 | 11.0 |
Graves' Disease/*genetics/immunology | 2 | 18.0 |
Antibodies, Monoclonal/diagnostic use | 4 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 3 | 0.0 |
Partial Pressure | 2 | 4.0 |
Diabetes Mellitus, Type 1/*genetics | 9 | 4.0 |
Body Water/chemistry | 2 | 50.0 |
Drug Therapy, Combination | 2 | 0.0 |
Genes, MHC Class II | 13 | 5.0 |
Prealbumin/metabolism | 2 | 10.0 |
Kinetics | 8 | 0.0 |
Receptors, Tumor Necrosis Factor | 3 | 1.0 |
Potassium/analysis | 2 | 11.0 |
*Sports | 4 | 12.0 |
China | 5 | 1.0 |
Philippines | 2 | 6.0 |
Consanguinity | 3 | 0.0 |
Factor XIII/genetics | 2 | 25.0 |
Israel | 2 | 1.0 |
Plasminogen/genetics | 2 | 33.0 |
Transferrin/genetics | 5 | 10.0 |
Vitamin D-Binding Protein/genetics | 3 | 11.0 |
alpha 1-Antitrypsin/genetics | 4 | 19.0 |
*Blood Circulation | 3 | 37.0 |
Psoriasis/*genetics | 2 | 3.0 |
HLA-B Antigens/genetics | 5 | 2.0 |
HLA-DQ Antigens/genetics | 5 | 1.0 |
*Physical Education and Training | 2 | 3.0 |
Major Histocompatibility Complex/genetics | 2 | 3.0 |
Schizophrenia/*genetics/immunology | 2 | 50.0 |
*Obesity | 2 | 3.0 |
Electrocardiography | 2 | 0.0 |
Respiration | 2 | 3.0 |
HLA Antigens/genetics/*immunology | 2 | 2.0 |
HLA-DR Antigens/genetics/immunology | 2 | 6.0 |
Genes, MHC Class I | 4 | 3.0 |
Complement 4/genetics/*immunology | 3 | 42.0 |
Disease Susceptibility | 7 | 0.0 |
Heterozygote | 5 | 0.0 |
Risk | 8 | 0.0 |
Kidney/metabolism | 2 | 0.0 |
*Electric Conductivity | 2 | 40.0 |
Tissue Distribution | 3 | 0.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Electrophoresis | 2 | 0.0 |
Multiple Sclerosis/*genetics | 2 | 2.0 |
*Renal Dialysis | 7 | 1.0 |
Monocytes/*metabolism | 2 | 0.0 |
Fingers/blood supply | 2 | 14.0 |
*Posture | 2 | 9.0 |
Reaction Time | 2 | 1.0 |
Spain/epidemiology | 2 | 1.0 |
Complement 3/analysis | 3 | 0.0 |
Complement 4/analysis | 3 | 1.0 |
Complement Activation | 3 | 1.0 |
Complement Pathway, Alternative | 2 | 1.0 |
Complement Pathway, Classical | 2 | 1.0 |
*Eating | 2 | 3.0 |
Esophagus/physiology | 2 | 22.0 |
*Exertion | 5 | 3.0 |
Fingers/*blood supply | 4 | 36.0 |
Forearm/blood supply | 2 | 4.0 |
Sweating | 2 | 22.0 |
HLA Antigens/immunology | 2 | 1.0 |
Lymphocytes/immunology | 2 | 0.0 |
Rosette Formation | 2 | 0.0 |
Liver/*enzymology | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
*Genes, MHC Class I | 3 | 1.0 |
*Genes, MHC Class II | 4 | 1.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
Histocompatibility Antigens Class II/analysis | 8 | 4.0 |
Psoriasis/*genetics/immunology | 2 | 15.0 |
Immunoelectrophoresis, Two-Dimensional | 4 | 3.0 |
Computers | 3 | 6.0 |
Disease Susceptibility/immunology | 2 | 2.0 |
HLA-D Antigens/*genetics | 3 | 2.0 |
Vascular Resistance/*physiology | 3 | 33.0 |
Haptoglobins/genetics | 3 | 6.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 4 | 7.0 |
*Genetic Markers | 9 | 2.0 |
Tunisia | 3 | 7.0 |
African Continental Ancestry Group/genetics | 3 | 1.0 |
Receptors, Fc/analysis | 2 | 3.0 |
Receptors, IgG | 2 | 1.0 |
Molecular Weight | 5 | 0.0 |
Neuraminidase | 3 | 8.0 |
Denmark | 2 | 1.0 |
HLA-A Antigens/genetics | 2 | 1.0 |
Recombination, Genetic | 7 | 0.0 |
Capillaries | 2 | 3.0 |
Carbon Dioxide/blood | 3 | 8.0 |
*Chromosomes, Human, Pair 6 | 2 | 0.0 |
Familial Mediterranean Fever/*genetics | 2 | 9.0 |
Lactoylglutathione Lyase/genetics | 12 | 27.0 |
Europe/ethnology | 2 | 2.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
*Heart-Assist Devices | 2 | 8.0 |
Nutritional Status | 3 | 2.0 |
Adipose Tissue/*metabolism | 2 | 1.0 |
Obesity/*physiopathology | 2 | 3.0 |
Finland | 4 | 1.0 |
Complement Factor B/*analysis | 4 | 50.0 |
Enzyme Precursors/*analysis | 5 | 38.0 |
Immunoglobulin Gm Allotypes/*analysis | 2 | 40.0 |
*Genes, Dominant | 4 | 1.0 |
Genetic Markers/analysis | 2 | 7.0 |
Enzyme Precursors/*genetics | 73 | 65.0 |
Muscles/*physiology | 2 | 7.0 |
HLA Antigens/analysis | 10 | 4.0 |
Immunoglobulin Allotypes/analysis | 2 | 22.0 |
Lipoproteins/*blood | 2 | 0.0 |
Rats, Inbred Strains | 4 | 0.0 |
Complement Factor B/classification/*genetics | 2 | 100.0 |
Deoxyribonucleases, Type II Site-Specific | 3 | 1.0 |
Blood Grouping and Crossmatching | 3 | 4.0 |
Deoxyribonuclease HpaII | 2 | 2.0 |
Complement Factor B/*genetics/isolation & purification | 2 | 100.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 5 | 11.0 |
Receptors, IgE | 6 | 9.0 |
Plethysmography | 4 | 12.0 |
Complement 3/genetics | 4 | 11.0 |
DNA, Recombinant | 2 | 1.0 |
Interleukin-1/physiology | 2 | 2.0 |
HLA-A1 Antigen | 2 | 22.0 |
HLA-B8 Antigen | 2 | 7.0 |
HLA-DR3 Antigen | 4 | 10.0 |
Arthritis, Rheumatoid/*genetics | 2 | 2.0 |
Arthritis, Rheumatoid/blood/*genetics | 2 | 66.0 |
Electrophoresis, Starch Gel | 2 | 1.0 |
Phosphoglucomutase/*genetics | 2 | 1.0 |
alpha 1-Antitrypsin/*genetics | 2 | 7.0 |
Chromatography, Gas | 2 | 2.0 |
Interleukin-4 | 4 | 4.0 |
Interleukins/*pharmacology | 3 | 4.0 |
*Prostatic Secretory Proteins | 5 | 5.0 |
*Gene Expression Regulation | 2 | 0.0 |
*Body Weight | 6 | 9.0 |
Parity | 3 | 2.0 |
Oxidation-Reduction | 2 | 0.0 |
Half-Life | 2 | 0.0 |
Colombia | 2 | 4.0 |
Isoelectric Focusing/methods | 3 | 10.0 |
*Genes, Structural | 4 | 0.0 |
*Bone Marrow Transplantation | 2 | 0.0 |
Complement 4a | 10 | 16.0 |
Complement 4b | 10 | 10.0 |
HLA Antigens/analysis/genetics | 2 | 7.0 |
Genes, Dominant | 5 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Models, Biological | 3 | 0.0 |
Immunoglobulin E/*metabolism | 2 | 12.0 |
Structure-Activity Relationship | 3 | 0.0 |
HLA-D Antigens/*analysis | 2 | 3.0 |
Diabetes Mellitus, Type 1/epidemiology/*genetics/immunology | 2 | 20.0 |
Clinical Trials | 2 | 0.0 |
Complement/analysis | 3 | 2.0 |
Immunoglobulin Allotypes/genetics | 2 | 11.0 |
Cross Reactions | 2 | 0.0 |
Histocompatibility Antigens/*analysis | 3 | 6.0 |
Genes | 2 | 0.0 |
Lactoylglutathione Lyase/*genetics | 8 | 19.0 |
Lyases/*genetics | 8 | 16.0 |
Arthritis, Rheumatoid/*immunology | 2 | 0.0 |
Complement 4/*analysis | 2 | 4.0 |
HLA Antigens/*analysis | 10 | 2.0 |
Immunoglobulin A/*analysis | 2 | 3.0 |
Enzymes/blood/*genetics | 2 | 33.0 |
Microscopy, Fluorescence | 2 | 0.0 |
*Heat | 2 | 1.0 |
Berlin | 2 | 66.0 |
*Energy Metabolism | 2 | 2.0 |
Drug Combinations | 3 | 0.0 |
Exertion | 3 | 4.0 |
Complement 4/immunology | 2 | 5.0 |
*HLA-B Antigens | 2 | 3.0 |
*Genes | 3 | 1.0 |
MNSs Blood-Group System/genetics | 2 | 18.0 |
Methods | 2 | 0.0 |
*Paternity | 4 | 5.0 |
Rh-Hr Blood-Group System/genetics | 2 | 7.0 |
Multiple Sclerosis/*genetics/immunology | 2 | 11.0 |
*Blood | 7 | 16.0 |
Calcimycin/pharmacology | 2 | 0.0 |
Histamine Release/*drug effects | 2 | 6.0 |
Immunodiffusion | 3 | 1.0 |
Anthropometry/*methods | 4 | 44.0 |
Arthritis, Rheumatoid/*genetics/immunology | 2 | 4.0 |
Jews | 3 | 4.0 |
*Acrylic Resins | 3 | 33.0 |
*Acrylonitrile/analogs & derivatives | 2 | 100.0 |
*Membranes, Artificial | 4 | 4.0 |
*Nitriles | 2 | 25.0 |
Ultrafiltration/instrumentation/*methods | 4 | 100.0 |
Acetates/administration & dosage | 2 | 100.0 |
Acrylic Resins | 2 | 8.0 |
Acrylonitrile/analogs & derivatives | 2 | 40.0 |
Ultrafiltration/*methods | 2 | 66.0 |
*Acid-Base Equilibrium | 3 | 20.0 |
Chromatography, DEAE-Cellulose | 2 | 3.0 |
Risk Assessment/methods | 2 | 7.0 |
Adrenal Hyperplasia, Congenital/*genetics | 2 | 8.0 |
Haploidy | 10 | 8.0 |
HLA-DR Antigens | 23 | 6.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Epidermis/pathology | 2 | 6.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Immunosuppression | 2 | 1.0 |
Leukocytes/immunology | 2 | 1.0 |
Mass Screening | 2 | 1.0 |
Milk, Human/analysis | 2 | 22.0 |
*Infant, Newborn | 2 | 4.0 |
HLA-B Antigens | 14 | 3.0 |
Lupus Erythematosus, Systemic/*genetics/immunology | 3 | 6.0 |
Saudi Arabia | 3 | 7.0 |
Histocompatibility Antigens Class II/*analysis | 3 | 2.0 |
*Lymphocyte Culture Test, Mixed | 2 | 3.0 |
Ethnic Groups | 5 | 2.0 |
Serum Albumin/immunology | 2 | 9.0 |
*Body Temperature Regulation | 3 | 10.0 |
Vasomotor System/*physiology | 2 | 22.0 |
Chromosomes, Human, 6-12 and X | 5 | 11.0 |
HLA-A Antigens | 9 | 2.0 |
Complement 4/deficiency/*genetics | 2 | 14.0 |
*Sweating | 2 | 66.0 |
*Lymphocyte Activation | 3 | 0.0 |
Precipitation | 2 | 1.0 |
Epitopes | 2 | 0.0 |
Social Class | 2 | 5.0 |
Absorption | 2 | 1.0 |
Cereals | 2 | 18.0 |
Fruit | 2 | 7.0 |
HLA-C Antigens | 6 | 4.0 |
Thigh | 2 | 7.0 |
*Chromosome Mapping | 6 | 0.0 |
*Chromosomes, Human, 6-12 and X | 4 | 2.0 |
Factor VIII/*genetics | 2 | 5.0 |
Factor VIIIa | 2 | 100.0 |
Paternity | 3 | 4.0 |
Neuraminidase/analysis | 2 | 100.0 |
Antibody-Dependent Cell Cytotoxicity | 3 | 3.0 |
Kidney Transplantation | 2 | 1.0 |
Germany, West | 4 | 8.0 |
*Lod Score | 3 | 8.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 2 | 2.0 |
Complement Factor B/immunology | 2 | 22.0 |
HLA Antigens | 3 | 2.0 |
Enzyme Precursors/*immunology | 2 | 22.0 |
Immunoelectrophoresis | 3 | 1.0 |
Homozygote | 3 | 0.0 |
Crossing Over, Genetic | 2 | 2.0 |
HLA Antigens/analysis/*genetics | 2 | 5.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
*Haploidy | 2 | 14.0 |
*HLA Antigens | 2 | 0.0 |
Mitomycins/pharmacology | 2 | 6.0 |
Cytochrome P-450 Enzyme System/*metabolism | 2 | 0.0 |
Stereoisomerism | 2 | 0.0 |
*Properdin | 2 | 50.0 |
Properdin/*analysis | 2 | 33.0 |
DNA, Viral/analysis | 2 | 0.0 |